Table 1

Equivalent therapeutic efficacy between QL1101 and bevacizumab was evaluated for the subgroups of baseline characteristics

	PFS (days)				OS (days)
	QL1101^a	Bevacizumab^b	HR (95% CI)^c	P^d	QL1101^a	Bevacizumab^b	HR (95% CI)^c	P^d
Age (years)
< 65	168	161	1.055 (0.8632–1.290)	0.2749	Undefined	Undefined	1.096 (0.7898–1.522	0.3025
≥ 65	132	140	1.311 (0.9113–1.885)	2.128	504	501	1.034 (0.6868–1.557)	0.0256
Gender
Male	153	151	1.109 (0.8834–1.392)	0.7947	475	Undefined	1.288 (0.9342–1.775)	2.384
Female	141	150.1	1.138 (0.8627–1.502)	0.8381	Undefined	Undefined	0.880 (0.5257–1.473)	0.2364
Smoking history
Never	152	168	1.121 (0.8803–1.429)	0.8611	Undefined	Undefined	1.050 (0.6841–1.610)	0.0491
Ever	164	139	1.173 (0.8267–1.665)	0.8001	462	Undefined	1.610 (0.9893–2.619)	3.674
Still	136	134	0.9681 (0.6633–1.413)	0.0283	Undefined	466	0.8480 (0.5057–1.422)	0.3905
Pathology
Wild type	150	144	1.058 (0.8448–1.325)	0.2409	Undefined	566	1.003 (0.7329–1.374)	0.0275
EGFR mutation	151.5	169	1.188 (0.8967–1.573)	1.44	Undefined	Undefined	1.617 (0.9382–2.788)	2.994
Tumor history
Yes	152	177	1.281 (0.7342–1.439)	0.7609	Undefined	Undefined	0.651 (0.2440–1.736)	0.7354
No	151	148.5	1.089 (0.9050–1.311)	0.8161	Undefined	Undefined	1.175 (0.8854–1.560)	1.249
ECOG
0	155	132	0.8692 (0.6022–1.255)	0.5599	Undefined	Undefined	1.700 (0.9502–3.040)	3.196
1	151	170	1.192 (0.9752–1.456)	2.938	Undefined	Undefined	1.010 (0.7423–1.375)	0.004

^aThe bevacizumab analogue was sourced from Qilu Pharmaceutical Co., Ltd, China. ^bBevacizumab was sourced from Roche, China. ^cHazard ratio (HR) [95% confidence interval (CI)]. ^dChi-square value using the Mantel-Cox test. PFS, progression free survival; OS, overall survival; ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor.